Atlas Trials

A Phase I Study of Mosunetuzumab for Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia

Clinical trial NCT05961696 · WITHDRAWN

Trial details

NCT number
NCT05961696
Sponsor
M.D. Anderson Cancer Center
Status
WITHDRAWN
Phase
Phase 1
Study type
INTERVENTIONAL
Refractory B-cell Acute Lymphoblastic Leukemia
Start date
2023-07-05
Primary completion
2023-10-03
Enrollment
0

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.